Annora Pharma has received final FDA approval for its Abbreviated New Drug Application (ANDA217329), bringing market implications as the generic alternative readies launch pending 180-day exclusivity. The regulatory clearance for the product marks a strategic milestone for Annora Pharma and is expected to capture significant market share as it enters the competitive landscape.